Does adding intraperitoneal paclitaxel to standard intraperitoneal regimen yield incremental survival? A propensity score-matched cohort study

Yen-Hou Chang¹,⁵†, Chien-Hsing Lu²,³,⁴,⁵†, Ming-Shyen Yen¹,⁵, Wai-Hou Lee¹,⁵, Yi Chang¹, Wei-Pin Chang⁶* and Chi-Mu Chuang¹,⁵*

Abstract

We recruited consecutive patients with stage III epithelial ovarian, tubal, and peritoneal cancers who had optimal residual tumor after primary cytoreductive surgery and who received intraperitoneal chemotherapy between 2002 and 2012. Two propensity score-matched sample cohorts were created. We found that the addition of paclitaxel as a second intraperitoneal agent on a 3-week dosing schedule did not yield significant incremental survival benefits over the intraperitoneal delivery of a single cisplatin-based regimen. If our findings could be confirmed by a prospective randomized study, then it would be interesting to explore the efficacy of shifting back to a dose-dense intraperitoneal delivery of paclitaxel or a dose-dense delivery of a new formulation of paclitaxel for the patients with stage III epithelial ovarian, tubal, and peritoneal cancers.

Keywords: Epithelial ovarian, tubal, and peritoneal cancer, Intraperitoneal chemotherapy, Propensity score, Survival, Clinical trials

Background

Currently, the standard intraperitoneal chemotherapy protocol for the treatment of stage III epithelial ovarian, tubal, and peritoneal cancers follows that of the Gynecologic Oncology Group (GOG) 114 trial (namely, intraperitoneal delivery of 100 mg/m² of cisplatin on day 2) [1] or the GOG 172 trial (intraperitoneal delivery of 100 mg/m² of cisplatin on day 2 and intraperitoneal delivery of 60 mg/m² of paclitaxel on day 8) [2]. These protocols share a common intravenous delivery of 135 mg/m² of paclitaxel on day 1. Importantly, the GOG 114 trial called for two cycles of a high dose of intravenous carboplatin (area under the curve, 9) before formal intraperitoneal treatment was administered. Although intraperitoneal chemotherapy has demonstrated superiority in the treatment of ovarian cancer, in clinical practice the completion rate of six assigned intraperitoneal cycles reached only 71% in the GOG 114 trial and 42% in the GOG 172 trial. Catheter-induced complications remain a major problem for patients who are unable to complete the assigned cycles [3].

In the present study, we compared the efficacy between GOG 114 and GOG 172 using survival as the primary end-point.

Patients and methods

We collected the clinical data of patients with stage III epithelial ovarian, tubal, and peritoneal cancer between January 2002 and December 2012 who were treated in the Institutional Review Board of Taipei Veterans General Hospital. Patients in the control cohort were treated according to the protocol described in the GOG 114 trial.
patients in the experimental cohort were treated according to the protocol described in the GOG 172 trial [2]. A flow chart describing the screening and matching process is shown in Fig. 1.

We used a propensity score-matching technique to compare two intraperitoneally treated cohorts of patients. The technique of propensity score, which is a covariate summary score, was used for the analysis in the present study [4, 5].

The matching procedure involved a two-step analysis. In step 1, we used 10 conditioning variables to develop propensity scores. In step 2, we used an algorithm of the nearest neighbor matching within a specified caliper distance (0.25 \( \sigma \) in the current study, where \( \sigma \) was the standard deviation of logit of propensity score) without replacement to create matched samples [6, 7]. Thus, for a given patient in the experimental group, we identified all of the patients in the control cohort whose propensity scores lay within a specified distance of that of the patient in the experimental group. From this restricted set of control patients, we matched the patient in the control group whose propensity score was closest to that of the patient in the experimental group. Eventually, this created two samples of equal size (1:1 matching).

We analyzed progression-free survival and overall survival in this study. All analyses were performed using STATA SE software, version 12 (Stata Corp., College Station, Texas, USA). \( P \) values less than 0.05 were considered statistically significant.

**Results**

The Kaplan–Meier progression-free survival and overall survival curves are shown in Fig. 2, with both intention-to-treat and per-protocol analyses. The median

---

**Fig. 1** Flow chart of the screening and propensity score-matching process
progression-free survival showed no difference between the control cohort and the experimental cohort (intention-to-treat analysis: 21.7 vs. 23.3 months, \( P = 0.646 \); per-protocol analysis: 21.6 vs. 26.8 months, \( P = 0.481 \)).

In addition, the median overall survival showed no significant difference between these two cohorts (intention-to-treat analysis: 61.5 vs. 63.4 months, \( P = 0.829 \); per-protocol analysis: 61.5 vs. 62.5 months, \( P = 0.697 \)) (Fig. 3).

**Discussion**

Whether based on intention-to-treat analysis or per-protocol analysis, we found no significant difference with respect to progression-free survival or overall survival between the control cohort and the experimental cohort. Our findings can be echoed by a detailed examination of the original GOG 114 and GOG 172 trials. In terms of progression-free survival, the advantage of median survival (intraperitoneal treatment group vs. intravenous treatment group) was not significantly different for the GOG 114 and GOG 172 trials (6.0 months [27.9 vs. 22.2 months] for the GOG 114 trial; 5.5 months [23.8 vs. 18.3 months] for the GOG 172 trial). The overall survival was longer in the GOG 172 trial (11.0 months [63.2 vs. 52.2 months] for the GOG 114 trial; 15.9 months [65.6 vs. 49.7 months] for the GOG 172 trial). However, in the GOG 172 trial, patients were recruited between March 1998 and January 2001; during this time, two drugs were available for second-line treatment: topotecan, which was approved in May 1996, and liposomal doxorubicin, which received accelerated approval in June 1999. These drugs may potentially extend post-progression survival and, thus, overall survival [8].

In summary, this propensity score-matching study of patients with stage III epithelial, tubal, and peritoneal cancers showed that patients in both the control cohort and the experimental cohort had similar survival outcomes, suggesting that the addition of a second intraperitoneal paclitaxel dose (administered every 3 weeks) to the current standard platinum-based intraperitoneal chemotherapy regimen does not yield significant incremental survival benefits. If our findings could be confirmed by a prospective randomized study, then it would be interesting to explore the efficacy of shifting back to a dose-dense intraperitoneal delivery of paclitaxel or a dose-dense delivery of a new formulation of paclitaxel for the patients with stage III epithelial ovarian, tubal, and peritoneal cancers.

**Authors’ contributions**

Conception and design: YHC, CHL, CMC. Provision of patients: YHC, CHL, MSY, WHL, YC, CMC. Collection and assembly of data: YHC, CHL, MSY, WHL, YC, CMC.
Data analysis and interpretation: WPC, CMC. Manuscript writing: WPC, CMC. All authors read and approved the final manuscript.

Author details
1 Institute of Clinical Medicine, School of Medicine, National Yang‑Ming University, Taipei 11221, Taiwan, China. 2 Department of Obstetrics and Gynecology, Taichung Veterans General Hospital, Taichung 40705, Taiwan, China. 3 Institute of Biomedical Sciences, National Chung Hsing University, Taichung 40227, Taiwan, China. 4 Rong‑Hsing Research Center for Translational Medicine, National Chung Hsing University, Taichung 40227, Taiwan, China. 5 Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei 11217, Taiwan, China. 6 Department of Healthcare Management, Yuan‑pei University, Hsinchu 30015, Taiwan, China.

Acknowledgements
This work was supported in part by the National Science Council, Taiwan, China (No. NSC 104‑NU‑E‑010‑004‑NU & MOST 103‑2410‑H‑264‑004).

Competing interests
The authors declare that they have no competing interests.

Received: 23 July 2015    Accepted: 14 April 2016
Published online: 09 May 2016

References
1. Markman M, Bundy BN, Alberts DS, Fowler JM, Clark‑Pearson DL, Carson LF, et al. Phase III trial of standard‑dose intravenous cisplatin plus paclitaxel versus moderately high‑dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small‑volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol. 2001;19(4):1001–7.
2. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354(1):34–43.
3. Walker JL, Armstrong DK, Huang HQ, Fowler J, Webster K, Burger RA, et al. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. Gynecol Oncol. 2006;100(1):27–32.
4. Austin PC. A critical appraisal of propensity‑score matching in the medical literature between 1996 and 2003. Stat Med. 2008;27(12):2037–49.
5. Ming K, Rosenbaum PR. Substantial gains in bias reduction from matching with a variable number of controls. Biometrics. 2000;56(1):118–24.
6. Sturmer T, Schneeweiss S, Brookhart MA, Rothman KJ, Avorn J, Glynn RJ. Analytic strategies to adjust confounding using exposure propensity scores and disease risk scores: nonsteroidal antiinflammatory drugs and short‑term mortality in the elderly. Am J Epidemiol. 2005;161(9):891–8.
7. Austin PC. The performance of different propensity score methods for estimating marginal hazard ratios. Stat Med. 2013;32(16):2837–49.
8. Ledermann JA, Kristeleit RS. Optimal treatment for relapsing ovarian cancer. Ann Oncol. 2010;21(Suppl 7):vii218–22.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre‑submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at www.biomedcentral.com/submit